Paper Details

  1. Home
  2. Paper Details

Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group.

Author: BerryScott, ErnstD Scott, HotteSébastien, LukkaHimu, WaldronTricia, WinquistEric

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Prostate cancer that returns after initial treatment or spreads is usually treated by reducing androgens, but most men eventually develop resistance. New studies on chemotherapy have prompted a review to identify the most effective non-hormonal systemic therapies for men with hormone-refractory prostate cancer (HRPC) and evidence of spread.
Paper Details　
Original Abstract of the Article :
Prostate cancer that has recurred after local therapy or disseminated distantly is usually treated with androgen deprivation therapy; however, most men will eventually experience disease progression within 12 to 20 months. New data emerging from randomized controlled trials (RCTs) of chemotherapy pr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550253/

データ提供：米国国立医学図書館（NLM）

Navigating the Treatment Landscape of Hormone-Refractory Prostate Cancer

Prostate cancer that progresses despite androgen deprivation therapy, known as hormone-refractory prostate cancer (HRPC), presents a significant challenge in cancer treatment. This research aims to identify the most effective non-hormonal systemic therapies for men with HRPC and metastases.

Finding Effective Alternatives: A Systematic Review of Non-Hormonal Therapies

The research conducted a systematic review of randomized controlled trials (RCTs) to evaluate the efficacy of non-hormonal systemic therapies for HRPC. This comprehensive analysis provides valuable insights into the current state of treatment options for this challenging cancer subtype.

Improving Outcomes for Men with Advanced Prostate Cancer

Imagine a world where men with HRPC can access effective treatment options that extend their lives and improve their quality of life. This research provides crucial information for healthcare providers and researchers seeking to improve outcomes for these patients. The findings highlight the need for continued research into non-hormonal therapies for HRPC, with the ultimate goal of developing better treatments for this devastating disease.

Dr. Camel's Conclusion

This research provides a valuable roadmap for navigating the complex landscape of hormone-refractory prostate cancer treatment. The systematic review highlights the importance of continued research into non-hormonal therapies for HRPC, with the aim of improving outcomes for men battling this challenging disease. By working together, researchers and clinicians can strive to develop more effective treatments and offer hope to those living with this cancer.

Date :
  1. Date Completed 2007-01-11
  2. Date Revised 2023-11-05
Further Info :

Pubmed ID

16670021

DOI: Digital Object Identifier

PMC1550253

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.